Future directions and combinations

Kareen outlines trials exploring time‑limited pirtobrutinib, triplets, other noncovalent BTK agents, and BTK degraders.

Play episode from 08:41

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!